Various Wall Street firms see nearly $1,000 per share within 12 months. And I will candidly admit -- that is a sober assessment. The ramp of supply, for two drugs they likely can sell unlimited amounts of -- at pretty outrageous prices. . . seems solid.
While the Roche preliminary look is promising -- as I have said right along, we need longer term data -- to see if there are off target effects, in the entire class. But the idea that Lilly had dropped from above $900, to around $850 tonight is plainly an over-reaction. Lilly has lots of capacity, and the market here is still unsaturated, in the higher end pockets of the US. I may not think that is an especially wise use of public health funding -- but one cannot deny that lots of people (already a lil' big-boned-ed) want it, and are paying well over $1,000 a month or are willing to do so. Here's the bit on the overbaked reaction to Roche's candidate:
. . .Roche shares jumped 5.8% in Wednesday’s trade. Meanwhile, shares of Wegovy-maker Novo Nordisk fell 4% by the European close, while Zepbound producer Eli Lilly was around 3% lower in U.S. late-morning trade.
Shares of Danish biotech company Zealand Pharma, which is also developing its own obesity treatment, fell 8.4%. . . .
Now you know -- onward, smiling widely. [Yes, this is a return to the power alley.] Be excellent to one another.
नमस्ते
No comments:
Post a Comment